Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

AVP-21D9

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2017
Review
2017
Background B. anthracis anti-toxin agents are approved and included in the Strategic National Stockpile based primarily on animal… Expand
  • figure 1
  • table 1
  • table 1
  • table 2
  • table 3
Is this relevant?
2014
2014
ABSTRACT Anthrax is an acute infectious disease caused by the spore-forming bacterium Bacillus anthracis. Timely administration… Expand
  • figure 1
  • table 1
  • table 2
  • table 3
  • figure 2
Is this relevant?
Review
2011
Review
2011
Recent FDA action (through, December 2010) related to Ezogabine, Ticagrelor, Naltrexone SR/bupropion, Clostridium difficile… Expand
Is this relevant?
Review
2010
Review
2010
Recent FDA action (through, October 2010) related to Qnexa, Linjeta, JZP-6, Bydureon, Zalbin, Staccato loxapine, Tapentadol… Expand
Is this relevant?
Highly Cited
2007
Highly Cited
2007
ABSTRACT Dutch-belted and New Zealand White rabbits were passively immunized with AVP-21D9, a human monoclonal antibody to… Expand
  • figure 1
  • figure 3
  • figure 2
  • figure 4
  • table 1
Is this relevant?
Highly Cited
2006
Highly Cited
2006
ABSTRACT Prevention of inhalation anthrax requires early and extended antibiotic therapy, and therefore, alternative treatment… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
2004
Highly Cited
2004
BackgroundPotent anthrax toxin neutralizing human monoclonal antibodies were generated from peripheral blood lymphocytes obtained… Expand
  • table 1
  • table 2
Is this relevant?
2004
2004
A panel of human anti-anthrax protective antigen IgG1 monoclonal antibodies were evaluated to determine the mechanism of toxin… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?